Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) said its LockeT suture retention device will be featured in live procedural cases at the International Symposium of Left Atrial Appendage (ISLAA) 2026, held March 5–6, 2026, in Los Angeles.
Company representatives will provide hands-on demonstrations for electrophysiology fellows and highlight LockeT benefits including potential cost reduction and same-day discharge.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
VTAK was down 0.69% pre-news while peer BJDX appeared in momentum scanners, moving up about 3.68%. Other peers showed mixed moves, pointing to stock-specific factors rather than a broad medical devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Asset sale, refocus | Positive | -6.5% | Sale of atherectomy catheter assets to strengthen balance sheet and refocus on EP. |
| Feb 17 | Strategic equity stake | Positive | +11.9% | Acquired 19.98% stake in Fly Flyte, adding AI-enabled aviation exposure. |
| Feb 12 | Institutional financing | Positive | -33.2% | Up to $36.5M strategic financing and ATM termination to bolster liquidity. |
| Feb 05 | LockeT conference cases | Positive | -4.8% | LockeT device featured in live procedural cases at Scripps conference. |
| Feb 04 | LockeT adoption update | Positive | +1.6% | Reported record January revenue and expanded hospital approvals for LockeT. |
News around balance-sheet actions and product visibility has often seen mixed or negative next-day moves, with only some growth or adoption headlines aligning positively with price.
Over the past month, VTAK announced several balance sheet and strategic moves, including an asset sale on Feb 19, 2026, a 19.98% stake acquisition in Fly Flyte on Feb 17, and up to $36.5 million in institutional financing on Feb 12. LockeT-specific news on Feb 4 and Feb 5 highlighted growing hospital adoption and live case exposure. Today’s ISLAA 2026 feature continues that LockeT visibility theme against a backdrop of recent financings and strategic portfolio shifts.
Market Pulse Summary
This announcement highlights additional clinical visibility for the LockeT suture retention device through live cases at ISLAA 2026, reinforcing recent efforts to showcase workflow and cost benefits. In context of asset sales, institutional financings up to $36.5 million, and expanding hospital adoption, investors may track whether repeated conference exposure translates into sustained revenue growth and broader electrophysiology market penetration for LockeT.
Key Terms
left atrial appendage medical
cardiac electrophysiology medical
suture retention device medical
AI-generated analysis. Not financial advice.
FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference. The event, co-hosted by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, will take place from March 5-6, 2026, at the Biltmore Hotel in Los Angeles, California.
The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic and Mt. Sinai will manage the program and content.
In addition, the ISLAA meeting provides a unique opportunity for hands-on demonstrations and product education for electrophysiology fellows. Catheter Precision will be participating in these sessions to provide fellows an opportunity to try LockeT, ask questions and learn more about the products benefits, which include cost reduction for the hospital and same day hospital discharge.
“We are proud that LockeT continues to gain traction at the industry's most prestigious gatherings,” said David Jenkins, CEO of Catheter Precision. “Our recent feature at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference underscores the importance of live clinical cases. They offer an unmatched opportunity for physicians to validate the efficiency and cost-effectiveness of our suture retention solutions in a real-world setting.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
When will Catheter Precision (VTAK) showcase LockeT at ISLAA 2026?
What demonstrations of LockeT will be available to electrophysiology fellows at ISLAA 2026?
Which clinical centers are involved in the ISLAA 2026 program featuring VTAK's LockeT?
What clinical benefits of LockeT does Catheter Precision highlight for ISLAA 2026 attendees?
How does Catheter Precision describe the value of live clinical cases for LockeT at conferences like ISLAA 2026?
